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Objectives. We attempted to demonstrate that theophylline, an 
adenosine receptor antagonist, can reverse bradyarrhythmias 
after orthotopic heart transplantation. 
Background. Sinus node dysfunction, primarily sinus bradycar- 
dia, frequently occurs after orthotopic heart transplantation and 
may lead to permanent pacemaker implantation. Endogenous 
adenosine has been implicated as a cause of such posttransplan- 
tation bradyarrhythmia. 
Methods. Twenty-nine transplant recipients (group 1) were 
given theophylline after bradyarrhythmias developed after trans- 
plantation. Data in these patients were compared with those in a 
control group of 18 patients without bradyarrhythmias (group 2) 
who were not given theophylline. 
Results. The mean heart rate in group 1 increased from 62 -+ 7 
to 89 -+ 10 beats/rain after administration of theophylline (p < 
0.0001); the mean heart rate in group 2 was 88 -+ 12 beats/min. 
Patients in group 1 required more days of temporary atrial pacing 
(3.5 -+ 1 vs. 1.5 - 3, p < 0.04) before the administration of 
theophylline than did patients in group 2. The length of hospital 
stay after transplantation did not differ significantly between 
groups 1 and 2 (17 +- 7.5 vs. 20 -+ 16 days, p = NS). Age, gender, 
underlying disease, preoperative use of amiodarone, graft isch- 
emia time or the incidence of moderate to severe rejection were 
not different between patient groups. 
Conclusions. The use of theophylline for posttransplantation 
bradyarrhythmias increased heart rate and facilitated the with- 
drawal of chronotropic support. We conclude that theophylline 
offers effective and specific therapy for heart transplant patients 
with early bradyarrhythmias, reducing the need for implantation 
of a permanent pacemaker. 
(J Am Coll Cardiol 1996;28:396-9) 
Sinoatrial node dysfunction, primarily sinus bradycardia, often 
complicates heart transplantation (1,2). Sinoatrial node dys- 
function early after transplantation is associated with a higher 
mortality rate (3), and as many as 21% of patients with 
bradyarrhythmias require permanent pacemaker implantation 
(1,4). However, because sinoatrial node dysfunction may be 
only transient (5), the requirement for pacing assistance de- 
creases progressively with time (6). Thus, a less invasive but 
effective alternative therapy would be desirable. 
Endogenously produced adenosine has been implicated in 
the pathogenesis of sinoatrial node dysfunction after trans- 
plantation (7). Indirect support for this hypothesis includes the 
observation that patients with sinoatrial node dysfunction 
often have angiographic disease in the sinus node artery that 
may lead to sinus node ischemia (8). Additionally, transplanted 
denervated hearts exhibit increased responsiveness to the 
negative dromotropic and chronotropic effects of adenosine 
(9,10). The mechanism responsible for this increased sensitiv- 
ity remains to be determined. 
Heart transplant recipients with bradycardia often have a 
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significantly prolonged sinus node recovery time (11-13). In 
these patients with bradycardia, theophylline, an adenosine 
receptor antagonist, has been shown not only to significantly 
shorten sinus node recovery time but also to increase heart rate 
(11-13). In contrast, theophylline seems to have little or no 
effect on the sinus node recovery time of patients without sinus 
node dysfunction (11,12). From these data, it is anticipated 
that theophylline would significantly increase heart rate in 
patients with bradyarrhythmias after orthotopic heart trans- 
plantation (7,14). To test this hypothesis and establish the 
clinical utility of theophylline for posttransplantation brady- 
arrhythmias, we examined the effect of this adenosine antago- 
nist on heart rate and rhythm of heart transplant recipients 
with bradycardia. 
Methods  
Forty-seven patients underwent orthotopic heart ransplan- 
tation in the period from March 1993 to December 1994. All 
patients received astandard cardioplegic solution that did not 
contain adenosine or adenosine triphosphate. The patients 
ranged in age from 16 to 66 years (mean 52); 85% were male. 
These 47 patients were classified into two groups on the basis 
of heart rate on postoperative day 4. Twenty-nine patients 
(group 1) had persistent bradycardia, frequent episodes of 
sinus arrest, or bradycardias that required positive chrono- 
tropic support with isoproterenol r temporary atrial pacing. 
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Table 1. Characteristics of Patients With (group 1) and Without 
(group 2) Bradycardia After Heart Transplantation 
Group 1 Group 2 
(n = 29) (n = 18) p Value 
Age (yr) 52 _+ 10 54 _+ 9 0.35 
Male/female 24/5 16/2 1 
Ischemic heart disease 20 (73%) 13 (72%) 1 
Preoperative use of amiodarone 11 (38%) 5 (28%) 0.26 
Data presented are mean value _+ SD or number (%) of patients in group. 
Bradycardia was defined as a heart rate consistently <70 
beats/min (1). Each of these patients received theophylline, 
300 mg intravenously followed by a mean dose _ SD of 474 _+ 
99 mg/day orally. The dose and duration of theophylline 
therapy were determined according to serum theophylline 
levels and the p~ttient's heart rate. In group 1, heart rate and 
rhythm were recorded before and 24 h after the initiation of 
theophylline therapy. The remaining 18 patients (group 2) had 
no bradycardia and did not receive theophylline. The heart 
rate in both groups was then followed up weekly for the next 6 
weeks. 
To determine the specificity of theophylline tosignificantly 
increase heart rate in patients with bradyarrhythmias after 
transplantation, theophylline (5 mg/kg body weight infused 
intravenously over 10 min) was administered to a separate 
group of 17 patients with coronary artery disease and normal 
heart rate at rest (group 3). Heart rate before and 10 min after 
theophylline infusion was recorded and compared with that in 
patients in group 1. This study was reviewed and approved by 
the University of Florida Institutional Review Board; all 
participants gave written informed consent. 
Data analysis. Groups 1 and 2 were compared with respect 
to age, gender, underlying disease, length of hospital stay, use 
of amiodarone, graft ischemia time, days requiring isoproter- 
enol and temporary atrial pacing and incidence of early graft 
rejection. In group 1, heart rates before and after theophylline 
were compared with one another and with heart rate in group 
2. The statistical significance of the effect of theophylline on 
heart rate in groups 1 and 3 was determined by using the 
Student t test for paired data. Heart rate in groups I and 2 was 
compared by two-way analysis of variance. All data are ex- 
pressed as mean value _+ SD. Differences were considered 
significant at p -< 0.05. 
Resul ts  
There were no significant differences between groups 1 and 
2 with respect o age, gender, underlying heart disease and the 
preoperative use of amiodarone (Table 1). Posttransplantation 
variables are summarized in Table 2. There were no significant 
differences with regard to graft ischemia time, days requiring 
isoproterenol, incidence of early rejection and length of hos- 
pital stay. Patients in group 1 required more days of temporary 
atrial pacing before the administration f theophylline than did 
Table 2. Variables After Heart Transplantation 
Group I Group 2 
(n - 29) (n = 18) p Value 
Baseline heart rate on postop 62 _+ 7 88 _+ 12 < 0.001 
day 4 (beats/rain) 
Days requiring atrial pacing 3.5 _+ 1 1.5 _+ 3 < 0.04 
Days requiring isoproterenol 3.8 _+ 1 3 _+ 1 0.34 
infusion 
Graft ischemia time (min) 163 _+ 18 166 _+ 28 0.55 
Incidence of moderate to severe 7% 17% 0.33 
early rejection 
Days of hospital stay after 17 _+ 7.5 20 _+ 16 0.41 
transplantation 
Unless otherwise indicated, data presented are mean value _+ SD. Groups 1 
and 2 as defined in Table 1; postop = postoperative. 
patients in group 2, but no patient from group 1 required 
temporary pacing after 24 h of maintenance theophylline. 
Positive ehronotropic effects of theophylline. Of the 29 
patients in group 1, 18 (62%) had sinus bradycardia, 7 (24%) 
had junctional bradycardia and 4 (14%) had sinus arrest with 
a slow ventricular response and were dependent on temporary 
pacing or isoproterenol to maintain heart rate at ->70 beats/ 
rain. Before administration f theophylline, patients in group 1 
had a mean heart rate of 62 __ 7 beats/min. Twenty-four hours 
after theophylline and in the absence of any other positive 
chronotropic support, he mean heart rate in group 1 increased 
to 89 __ 10 beats/min (p < 0.0001) and did not differ signifi- 
cantly from that (88 _+ 12 beats/min) in group 2 (Table 2). 
During 6 weeks of follow-up, the mean heart rate of the 29 
patients in group 1 did not differ from the rate in group 2 (Fig. 
1), but 3 of the 29 did require permanent atrial pacemaker 
implantation i contrast o 0 of the 18 patients in group 2. 
Figure 1, Positive chronotropic effect of theophylline on bradycardia 
after heart ransplantation. Heart ransplant recipients with bradycar- 
dia on postoperative day 4 (group 1, n = 29) were treated with 
theophylline, 300 mg intravenously followed by 474 -+ 99 mg/day orally. 
Patients who did not require positive chronotropic therapy after 
postoperative day 4 (group 2, n = 18) were not treated with theoph- 
ylline. Theophylline promptly increased the heart rates of group 1 to 
values equal to those in group 2. The positive chronotropic effects of 
theophylline were sustained throughout the 6-week follow-up eriod. 
bpm = beats per minute. 
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Figure 2. Effect of theophylline on heart rate in group 1 (29 heart 
transplant recipients with bradycardia [Brady TX Pts]) and group 3 (17 
patients with heart disease without ransplantation a d normal heart 
rate [Non-TX Controls]). The heart rates were measured before (pre) 
and after (post) the administration f 300 mg of theophylline intrave- 
nously. Theophylline significantly (*p < 0.05) increased the heart rate 
in group 1 but not in group 3. Data reported are mean value _+ SD. 
bpm = beats per minute. 
Review of the data for these three patients demonstrated that 
the initial increase in heart rate produced by theophylline 
could not be maintained by day 3 of drug administration 
although serum levels were adequate (>12 mg/dl). Among the 
remaining 26 patients in group 1, theophylline administration 
could be discontinued in all but 1 patient within 6 weeks 
without decreasing heart rate to <70 beats/min. 
Specificity of theophylline for patients with bradycardia. 
The effect of theophylline appeared to be specific for the 
transplant patients with bradycardia. In group 3, the separate 
group of 17 patients with heart disease without heart trans- 
plantation whose heart rate was considered normal (i.e., no 
evidence of sinus node dysfunction), theophylline at a dose 
similar to that used in group 1 did not significantly affect heart 
rate. As illustrated in Figure 2, heart rate in group 3 increased 
insignificantly from 69 _ 10 beats/min at baseline to 77 -+ 12 
beats/min after theophylline in contrast to the significant 
increase (from 62 _+ 7 beats/rain at baseline to 89 + 10 
beats/min after theophylline, p < 0.0001) noted in group 1. 
Theophylline dose and concentration. In 19 patients from 
group 1 whose serum levels of theophylline were measured, a 
theophylline dose of 474 _ 99 rag/day produced a serum 
concentration of 15.7 +_ 3 mg/dl. All but 1 of the 29 patients in 
group 1 tolerated theophylline well; that patient experienced 
nausea that could be directly attributed to theophylline. 
Discussion 
Our data demonstrate hat theophylline reverses -90% of 
bradycardia occurring early after orthotopic heart ransplanta- 
tion and facilitates withdrawal of positive chronotropic ther- 
apy. The effect of theophylline in the transplant recipients with 
bradycardia was prompt, specific and sustained. We propose 
that this effect of theophylline is due to antagonism of the 
Al-receptor-mediated effects of endogenous adenosine (15,16), 
which may play a role in the etiology of sinoatrial node dys- 
function after transplantation. Theophylline, at the plasma 
concentrations measured, is likely to act primarily as an 
adenosine receptor antagonist, with little or no effect on the 
level of circulating catecholamines or inhibition of phospho- 
diesterase (17). However, we cannot exclude the possibility 
that theophylline increased the positive chronotropic effect of 
circulating catecholamines bycausing a rightward shift of the 
concentration-response curve. Nevertheless, during conditions 
of increased concentrations of myocardial interstitial adeno- 
sine and clinically significant sinoatrial node dysfunction, A1- 
adenosine receptor antagonism not only would reverse the 
direct depressant effects of adenosine on the sinoatrial node, 
but also should reverse the anti-beta-adrenergic actions of 
adenosine and, hence, augment the cardiostimulatory effects of 
circulating catecholamines. 
Specificity of theophylline. Preliminary data from our and 
other laboratories (11,12) demonstrate hat the effect of the- 
ophylline is specific for heart transplant recipients with brady- 
cardia. For instance, intravenous administration of theophyl- 
line (300 rag) significantly shortened the corrected sinus node 
recovery time and Wenckebach cycle length of transplant 
recipients with bradycardia but had no significant effect on 
either variable in transplant recipients with a normal heart rate 
(11). Recently, other investigators (12,13) have also reported 
that theophylline promptly and specifically shortens the cor- 
rected sinus node recovery time of heart transplant recipients 
with sinoatrial node dysfunction. Because of the specificity of 
action, it is tempting to propose that selective Al-adenosine 
receptor antagonists, rather than sympathomimetic drugs, 
would be more appropriate therapy for bradycardia complicat- 
ing recovery early after heart transplantation. 
Prevalence of sinoatrial node dysfunction. Sixty-two per- 
cent of our study patients exhibited early sinoatrial node 
dysfunction. Other investigators (1,3,7,14) have reported the 
occurrence of sinoatrial node dysfunction in 18% to 50% of 
orthotopic heart transplant recipients. The apparent higher 
incidence of bradycardia mong our patients is likely due to 
the criterion we used to define sinoatrial node dysfunction 
(heart rate <70 beats/rain). This definition of sinus node 
dysfunction was based on findings of Heinz et al. (1), who 
found that heart transplant recipients with a postoperative 
heart rate <70 beats/min were at risk for long-term sinoatrial 
node dysfunction and warranted close follow-up. 
Other causes of bradyarrhythmias after heart transplanta- 
tion. Preoperative use of amiodarone, prolonged graft isch- 
emia and early rejection have all been associated with brady- 
arrhythmias inheart ransplant recipients. However, consistent 
with the results of others (18), preoperative use of amiodarone 
in our study did not result in a higher incidence of bradycardia 
after transplantation. Previous tudies (2,5,9) have reported an 
association of prolonged graft ischemia with transient sinoatri- 
al node dysfunction. In the present study, we found no 
association between the duration of graft ischemia time and 
bradyarrhythmias. Although Haught (19), Ellenbogen (7), 
Blanche (20) and their coworkers found an association be- 
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tween moderate to severe rejection and episodes of significant 
bradyarrhythmias, in our study group, bradyarrhythmias were 
not associated with early heart transplant rejection. 
Cost-effectiveness of theophylline for bradyarrhythmias 
after heart transplantation. According to published data 
(1,2,4), 50% of heart transplant recipients will manifest brady- 
cardia early after transplantation, and 40% of these patients 
with bradycardia will receive a permanent pacemaker. How- 
ever, with the use of theophylline as chronotropic therapy for 
these patients with bradycardia will reduce the need for 
permanent pacing to only 10%. This reduction would result in 
savings of -$650/transplant patient based on cost of chrono- 
tropic therapy alone. 
On the basis of these observations, we propose that in 
patients with bradyarrhythmias early after transplantation, 
theophylline can be useful to increase heart rate, facilitate 
withdrawal of positive chronotropic support and avoid unnec- 
essary permanent pacemaker implantation. However, because 
of the relatively small number of patients in our study, the 
efficacy and usefulness of theophylline in the management of
bradyarrhythmias complicating the postoperative course of 
heart ransplant recipients will require further evaluation. The 
role of endogenous adenosine as the mediator of sinoatrial 
node dysfunction and the use of adenosine receptor antago- 
nists that are more specific, selective and potent for the 
Al-adenosine receptor subtype than theophylline should also 
be investigated. 
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